Profile data is unavailable for this security.
About the company
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing Immediate Immunity against each of the three causes of calf scours (E. coli, coronavirus, and rotavirus).
- Revenue in USD (TTM)21.28m
- Net income in USD-3.90m
- Incorporated1987
- Employees74.00
- LocationImmuCell Corp56 Evergreen DrivePORTLAND 04103United StatesUSA
- Phone+1 (207) 878-2770
- Fax+1 (302) 655-5049
- Websitehttps://immucell.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aspira Women's Health Inc | 8.99m | -14.74m | 30.75m | 64.00 | -- | -- | -- | 3.42 | -1.33 | -1.33 | 0.8698 | -0.1104 | 0.9637 | 13.76 | 5.83 | 140,484.40 | -158.00 | -110.58 | -395.41 | -151.88 | 58.84 | 45.23 | -163.95 | -334.08 | 1.11 | -- | 3.10 | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 32.00m | 1.00 | -- | 0.1787 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
Apollomics Inc | 0.00 | -388.09m | 32.38m | -- | -- | 0.4788 | -- | -- | -4.34 | -4.34 | 0.00 | 0.6225 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,391.69 | 0.012 | -- | -- | -- | -154.03 | -- | -- | -- |
IGC Pharma Inc | 1.22m | -14.15m | 32.41m | 61.00 | -- | 3.43 | -- | 26.65 | -0.2479 | -0.2479 | 0.0217 | 0.142 | 0.0776 | 0.2084 | 7.09 | 19,934.43 | -90.30 | -33.35 | -100.90 | -35.84 | 51.40 | 8.74 | -1,163.24 | -410.26 | 0.8564 | -- | 0.0153 | -- | 129.47 | -16.11 | 23.38 | -- | 25.28 | -- |
Goldenwell Biotech Inc | 1.08k | -114.27k | 32.42m | -- | -- | 603.21 | -- | 30,020.83 | -0.0012 | -0.0012 | 0.00001 | 0.0005 | 0.0052 | 0.0035 | -- | -- | -54.62 | -- | -54.97 | -- | 43.52 | -- | -10,580.56 | -- | 20.18 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
Unicycive Therapeutics Inc | 0.00 | -37.82m | 33.09m | 14.00 | -- | -- | -- | -- | -1.26 | -1.26 | 0.00 | 0.5779 | 0.00 | -- | -- | 0.00 | -92.81 | -218.20 | -221.58 | -609.54 | -- | -- | -- | -3,877.49 | -- | -- | 0.00 | -- | -29.02 | -- | -73.95 | -- | -- | -- |
ImmuCell Corp | 21.28m | -3.90m | 33.20m | 74.00 | -- | 1.34 | -- | 1.56 | -0.5030 | -0.5030 | 2.75 | 3.18 | 0.494 | 2.29 | 9.03 | 269,401.50 | -9.05 | -5.16 | -9.97 | -5.53 | 27.55 | 40.04 | -18.31 | -12.64 | 1.00 | -8.14 | 0.3204 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
Nuo Therapeutics Inc | 782.01k | -3.02m | 33.83m | -- | -- | 99.50 | -- | 43.26 | -0.071 | -0.071 | 0.0183 | 0.0075 | 0.4516 | 0.7856 | 4.30 | -- | -174.64 | -116.16 | -294.62 | -354.84 | 78.74 | 70.02 | -386.76 | -854.53 | 1.01 | -1,418.93 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
Brainstorm Cell Therapeutics Inc | 0.00 | -15.53m | 34.10m | 29.00 | -- | -- | -- | -- | -0.3227 | -0.3227 | 0.00 | -0.0811 | 0.00 | -- | -- | 0.00 | -276.90 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
Rapid Micro Biosystems Inc | 23.10m | -51.90m | 34.29m | 193.00 | -- | 0.3231 | -- | 1.48 | -1.20 | -1.20 | 0.5355 | 2.48 | 0.1535 | 1.37 | 4.34 | 119,663.20 | -34.49 | -- | -38.20 | -- | -22.59 | -- | -224.73 | -- | 5.62 | -- | 0.0028 | -- | 31.44 | -- | 13.71 | -- | -- | -- |
Estrella Immunopharma Inc | 0.00 | -2.16m | 34.44m | -- | -- | 3.31 | -- | -- | -1.90 | -1.90 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -5.92 | -- | -7.86 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -302.11 | -- | -- | -- |
Marker Therapeutics Inc | 3.32m | -12.21m | 34.52m | 8.00 | -- | 2.92 | -- | 10.39 | -1.38 | -0.636 | 0.3751 | 1.32 | 0.158 | -- | 1.69 | 415,107.50 | -58.12 | -53.74 | -70.75 | -62.25 | -- | -- | -367.79 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
Promis Neurosciences Inc | 0.00 | -11.89m | 34.93m | 6.00 | -- | 453.00 | -- | -- | -0.8292 | -0.8292 | 0.00 | 0.0041 | 0.00 | -- | -- | 0.00 | -298.08 | -144.28 | -- | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
LianBio - ADR | 0.00 | -87.98m | 35.50m | 163.00 | -- | 0.174 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
Cara Therapeutics Inc | 16.94m | -122.54m | 35.51m | 55.00 | -- | 1.19 | -- | 2.10 | -2.26 | -2.26 | 0.3118 | 0.5452 | 0.1392 | 1.34 | 4.35 | 307,963.60 | -100.70 | -35.76 | -115.83 | -40.82 | 75.18 | -- | -723.49 | -162.10 | 5.20 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 216.33k | 2.79% |
Renaissance Technologies LLCas of 31 Mar 2024 | 124.89k | 1.61% |
Cresset Asset Management LLCas of 31 Mar 2024 | 103.61k | 1.34% |
Bleichroeder LPas of 31 Mar 2024 | 101.59k | 1.31% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 64.72k | 0.84% |
Dimensional Fund Advisors LPas of 31 Mar 2024 | 63.40k | 0.82% |
Shufro, Rose & Co. LLCas of 31 Mar 2024 | 62.41k | 0.81% |
Geode Capital Management LLCas of 31 Mar 2024 | 53.21k | 0.69% |
Overbrook Management Corp.as of 31 Mar 2024 | 32.86k | 0.42% |
Strategic Financial Services, Inc. (New York)as of 31 Mar 2024 | 31.00k | 0.40% |